CSTL
Castle Biosciences, Inc. Common Stock
stockNASDAQ
castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 35.93 | 2026-09-28 | -1.10% | 1.342 |
| 1M | 32.91 | 2026-09-04 | +7.98% | 0.113 |
| 3M | 24.21 | 2026-07-06 | +46.78% | 1.392 |
| 6M | 24.73 | 2026-04-06 | +43.69% | 0.874 |
| 1Y | 22.72 | 2025-10-03 | +56.40% | 0.861 |
| 2Y | 29.35 | 2024-10-04 | +21.07% | — |
| 5Y | 60.44 | 2021-10-04 | -41.21% | 1.417 |
Castle Biosciences, Inc. Common Stock (NASDAQ:CSTL) stock price today is $35.54, and today's volume is 167,719. CSTL is up 0.794% today. The 30 day average volume is 358,077. CSTL market cap is $1.09B with 30.55M shares outstanding.